Keyword: Gilead Sciences


5. Epclusa and Harvoni

Thanks to high rebates and payer hardball, Gilead is in a tough spot with its hepatitis C drugs, including its all-genotype treatment Epclusa and the once-high-flying Harvoni. In response, the company did something previously unheard of in pharma.

9. Letairis

Gilead’s recent troubles in hepatitis C aside, the company isn't challenge-free. It has a big patent loss coming this year for Letairis, approved in 2007 and used to treat pulmonary arterial hypertension.